TABLE 1.

Comparisons of baseline characteristics among treatment groups for total KEEPS

Variable	n	No. (%) missing	PBO (n = 275)	t-E2 (n = 222)	o-CEE (n = 230)	P
Age, y	726	1 (<1%)	52.5 ± 2.5	52.7 ± 2.6	52.8 ± 2.6	0.394
White, by self-report	690	37 (5%)	210 (80%)	169 (82%)	176 (80%)	0.863
Weight, kg	727	0	71.1 ± 12.2	69.9 ± 12.0	69.7 ± 11.9	0.322
Height, cm	727	0	164.1 ± 6.2	163.9 ± 6.1	163.6 ± 6.3	0.748
Body mass index, kg/m2	727	0	26.4 ± 4.3	26.0 ± 4.4	26.0 ± 4.3	0.502
Waist circumference, cm	712	15 (2%)	84.9 ± 12.0	83.8 ± 11.8	84.2 ± 11.3	0.566
Systolic blood pressure, mm Hg	727	0	119.8 ± 14.4	117.3 ± 15.8	118.9 ± 14.5	0.158
Diastolic blood pressure, mm Hg	727	0	75.3 ± 9.5	74.0 ± 9.7	75.2 ± 8.3	0.237
Total cholesterol, mg/dL	727	0	216.7 ± 30.4	215.2 ± 33.6	214.7 ± 32.1	0.759
Low-density cholesterol level, mg/dL	727	0	130.5 ± 29.3	127.8 ± 31.1	127.5 ± 27.9	0.459
High-density cholesterol level, mg/dL	727	0	63.8 ± 16.2	66.2 ± 18.5	66.4 ± 18.0	0.176
Triglyceride level, mg/dLa	727	0	92.7 ± 51.5	89.0 ± 45.6	89.3 ± 52.0	0.658
Menopausal symptoms
Hot flash symptoms by historyb	727	0	126 (46%)	92 (41%)	100 (43%)	0.617
Night sweats by historyb	727	0	99 (36%)	72 (32%)	83 (36%)	0.643
Mood swingsb	727	0	43 (16%)	38 (17%)	34 (15%)	0.789
Depressionb	727	0	21 (8%)	19 (9%)	23 (10%)	0.641
Trouble sleepingb	727	0	93 (34%)	78 (35%)	66 (29%)	0.297
Irritabilityb	727	0	42 (15%)	42 (19%)	39 (17%)	0.559

KEEPS, the Kronos Early Estrogen Prevention Study; o-CEE, oral conjugated equine estrogen; PBO, placebo; t-E2, transdermal estradiol.

^aVariable was transformed to the natural logarithmic scale before performing the statistical testing so that the test assumptions were not violated.

^bSeverity scales for menopausal symptoms were dichotomized as binary to indicate a response of either “moderate” or “severe.”